Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 5
2009 4
2010 4
2011 4
2012 3
2013 4
2014 9
2015 8
2016 9
2017 8
2018 9
2019 7
2020 5
2021 7
2022 1
2023 1
2024 2
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
Population-Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis.
Witzel S, Huss A, Nagel G, Rosenbohm A, Rothenbacher D, Peter RS, Bäzner H, Börtlein A, Dempewolf S, Schabet M, Hecht M, Kohler A, Opherk C, Naegele A, Sommer N, Lindner A, Alexudis C, Bachhuber F, Halbgebauer S, Brenner D, Ruf W, Weiland U, Mayer B, Schuster J, Dorst J, Tumani H, Ludolph AC; and the ALS Registry Swabia Study Group. Witzel S, et al. Ann Neurol. 2024 Dec;96(6):1040-1057. doi: 10.1002/ana.27054. Epub 2024 Aug 23. Ann Neurol. 2024. PMID: 39177232
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. NPJ Parkinsons Dis. 2025 Jul 1;11(1):193. doi: 10.1038/s41531-025-01041-9. NPJ Parkinsons Dis. 2025. PMID: 40593721 Free PMC article.
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Taylor KI, Lipsmeier F, Scelsi MA, Volkova-Volkmar E, Rukina D, Popp W, Lambrecht S, Anzures-Cabrera J, Summers D, Abt M, Monnet A, Kilchenmann T, Schjodt-Eriksen J, Essioux L, Kustermann T, Zago W, Svoboda H, Nikolcheva T, Postuma RB, Pagano G, Lindemann M; PASADENA Investigators; Prasinezumab Study Group. Taylor KI, et al. NPJ Digit Med. 2025 Jun 16;8(1):365. doi: 10.1038/s41746-025-01572-8. NPJ Digit Med. 2025. PMID: 40523921 Free PMC article.
[Amyotrophic lateral sclerosis. Multisystem degeneration].
Hübers A, Ludolph AC, Rosenbohm A, Pinkhardt EH, Weishaupt JH, Dorst J. Hübers A, et al. Among authors: pinkhardt eh. Nervenarzt. 2016 Feb;87(2):179-88. doi: 10.1007/s00115-015-0030-8. Nervenarzt. 2016. PMID: 26646612 Review. German.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Ocular motor abnormalities in Parkinsonian syndromes.
Pinkhardt EH, Kassubek J. Pinkhardt EH, et al. Parkinsonism Relat Disord. 2011 May;17(4):223-30. doi: 10.1016/j.parkreldis.2010.08.004. Epub 2010 Aug 30. Parkinsonism Relat Disord. 2011. PMID: 20801069 Review.
[Optical Coherence Tomography (OCT)--a new diagnostic tool in psychiatry?].
Schönfeldt-Lecuona C, Schmidt A, Pinkhardt EH, Lauda F, Connemann BJ, Freudenmann RW, Gahr M. Schönfeldt-Lecuona C, et al. Among authors: pinkhardt eh. Fortschr Neurol Psychiatr. 2014 Oct;82(10):566-71. doi: 10.1055/s-0034-1385024. Epub 2014 Oct 9. Fortschr Neurol Psychiatr. 2014. PMID: 25299627 Review. German.
Manual MRI morphometry in Parkinsonian syndromes.
Möller L, Kassubek J, Südmeyer M, Hilker R, Hattingen E, Egger K, Amtage F, Pinkhardt EH, Respondek G, Stamelou M, Möller F, Schnitzler A, Oertel WH, Knake S, Huppertz HJ, Höglinger GU. Möller L, et al. Among authors: pinkhardt eh. Mov Disord. 2017 May;32(5):778-782. doi: 10.1002/mds.26921. Epub 2017 Feb 2. Mov Disord. 2017. PMID: 28150443
80 results